Reneo Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate. Co.'s primary product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta. Co. is developing REN001 in rare genetic diseases that typically present with myopathy and have high unmet medical needs, including primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. We show 12 historical shares outstanding datapoints in our RPHM shares outstanding history coverage, used to compute RPHM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RPHM market cap history over the course of time is important for investors
interested in comparing RPHM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RPHM versus a peer is one thing; comparing
RPHM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RPHM can fluctuate over the course of history.
With this page we aim to empower investors researching RPHM by allowing them to research the RPHM market cap history. |
Free RPHM Email Alerts:
Video: The Importance of Market Cap
